Michael Joseph Plunkett Net Worth

The estimated Net Worth of Michael Joseph Plunkett is at least $1.09 Million dollars as of 24 August 2017. Michael Plunkett owns over 75,000 units of Alphatec Inc stock worth over $1,090,692 and over the last 11 years Michael sold ATEC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Michael Plunkett ATEC stock SEC Form 4 insiders trading

Michael has made over 2 trades of the Alphatec Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Michael exercised 75,000 units of ATEC stock worth $408,750 on 24 August 2017.

The largest trade Michael's ever made was exercising 75,000 units of Alphatec Inc stock on 24 August 2017 worth over $408,750. On average, Michael trades about 6,923 units every 57 days since 2014. As of 24 August 2017 Michael still owns at least 200,127 units of Alphatec Inc stock.

You can see the complete history of Michael Plunkett stock trades at the bottom of the page.

What's Michael Plunkett's mailing address?

Michael's mailing address filed with the SEC is C/O ALPHATEC SPINE, INC., 5818 EL CAMINO REAL, CARLSBAD, CA, 92008.

Insiders trading at Alphatec Inc

Over the last 18 years, insiders at Alphatec Inc have traded over $1,216,108,242 worth of Alphatec Inc stock and bought 24,460,197 units worth $141,338,962 . The most active insiders traders include Mortimer Iii Berkowitz, John Foster, and Llc Hgp. On average, Alphatec Inc executives and independent directors trade stock every 24 days with the average trade being worth of $1,610,824. The most recent stock trade was executed by Evan Bakst on 23 August 2024, trading 35,000 units of ATEC stock currently worth $201,600.

What does Alphatec Inc do?

as a medical technology company, we improve lives by providing innovative spine surgery solutions through our relentless pursuit of superior outcomes. we are dedicated to the design, development, launch and the delivery of spinal fusion products. we seek to accomplish this by working with spine surgeons to design and develop products and systems that address the entire spinal fusion procedure in the most effective and efficient way possible. our product designs and platforms provide innovation through a focus on simplifying procedures for the surgeon with the ultimate objective of superior outcomes. alphatec spine is seeking growth through innovation and continually developing technologies that will have a greater positive impact on patient care and outcomes. please visit our website for more information: www.alphatecspine.com

Complete history of Michael Plunkett stock trades at Alphatec Inc

Alphatec Inc executives and stock owners

Alphatec Inc executives and other stock owners filed with the SEC include:

• Patrick Miles,
  Chairman of the Board, President, Chief Executive Officer
• David Sponsel,
  Executive Vice President - Sales
• Jeffrey Black,
  Chief Financial Officer, Executive Vice President
• Patrick S. Miles,
  Exec. Chairman, CEO & Pres
• Craig Hunsaker,
  Executive Vice President - People & Culture, General Counsel
• David P. Sponsel,
  Exec. VP of Sales
• Craig E. Hunsaker,
  Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel
• Donald Williams,
  Independent Director
• Ward Woods,
  Independent Director
• Quentin Blackford,
  Independent Director
• David Mowry,
  Independent Director
• Jeffrey Rydin,
  Director
• James Tullis,
  Independent Director
• Jason Hochberg,
  Independent Director
• Evan Bakst,
  Independent Director
• Karen McGinnis,
  Independent Director
• Josh Berg,
  IR Contact Officer
• David Pelizzon,
  Director
• Mortimer Berkowitz,
  Lead Independent Director
• Mark Ojeda,
  Executive Vice President - Cervical & Biologics
• Kelli Howell,
  Executive Vice President - Clinical Strategies
• Eric Dasso,
  Executive Vice President - Adjunctive Technologies
• Brian Snider,
  Executive Vice President - Marketing and Development
• Mark D. Ojeda,
  Exec. VP of Cervical & Biologics
• Kelli Mari Howell,
  Exec. VP of Clinical Strategies
• Dr. Luiz Pimenta,
  Chief Medical Officer
• Jonathan Allen,
  Exec. VP of Commercial Operations
• Brian R. Snider,
  Exec. VP of Marketing
• Scott Lish,
  Sr. VP of R&D
• J. Todd Koning,
  Chief Financial Officer
• Terry M. Rich,
  President & COO
• Leslie H Cross,
  Director
• Dennis Nelson,
  VP, Finance and Controller
• Stephen Oneil,
  Director
• Siri S Marshall,
  Director
• R Ian Molson,
  Director
• James Corbett,
  President and CEO
• Jonathan Allen,
  EVP, Commerical Operations
• Michael Joseph Plunkett,
  Chief Operating Officer
• Michael O'neill,
  CFO and Vice President
• John Foster,
  Director
• Ebun Garner,
  VP, Legal Affairs & Compliance
• Jennifer N. Pritzker,
  10% owner
• David M Demski,
  
• Keith Valentine,
  
• Healthcare Partners, Llc Se...,
  
• Mitsuo Asai,
  President, Alphatec Pacific
• Tom C Davis,
  Director
• James R Glynn,
  Director
• Rohit M Desai,
  Director
• Luke T Faulstick,
  Director
• William Patrick Ryan,
  Chief Operating Officer
• Partners Ii L P Healthpoint...,
  10% owner
• Ii, Llc Hgp,
  10% owner
• Ross Simmonds,
  Senior VP, Sales & Marketing
• Stephen Lubischer,
  VP, Sales
• Reinecke Steven,
  VP, Research & Development
• Richard Ravitch,
  Director
• Oliver Burckhardt,
  President, International
• Kermit P. Stott,
  VP, Operations
• Co Invest Vehicle Ii, L.P. ...,
  10% owner
• Peter C Wulff,
  CFO, VP and Treasurer
• Dirk Kuyper,
  President and CEO
• Brian Plotkin,
  VP, Information Technology
• Jens Peter Timm,
  VP, Research and Development
• Stephen Hochschuler,
  Director
• Corp Chubb,
  10% owner
• Partners Lp Healthpoint Cap...,
  10% owner
• Llc Hgp,
  10% owner
• Ii, Llchealthpointcapital P...,
  
• Herbert J Bellucci,
  VP, Manufacturing
• Stephen T D Dixon,
  CFO, VP and Treasurer
• Vicky Romanoski,
  Chief Admin Ofcr, VP & Scrty
• Insurance Co Federal,
  10% owner
• Daniel Lacienski,
  Executive VP, Operations
• Kimberly Bradshaw,
  VP, Physician Services
• Steven Yasbek,
  CFO, Treasurer and V.P.
• Shunshiro Yoshimi,
  
• Ronald Hiscock,
  President & CEO
• Scott Weise,
  VP, Business Dev. & Marketing
• Trent Northcutt,
  VP, Sales
• John Todd Koning,
  CHIEF FINANCIAL OFFICER
• Marie Meynadier,
  
• Elizabeth Ann Altman,
  
• Paul Segal,
  
• Tyson Eliot Marshall,
  GENERAL COUNSEL & CORP. SEC.
• Andy Barnett,
  Director
• Scott Lish,
  CHIEF OPERATING OFFICER